Merck & Co., Inc. (NYSE:MRK) shares were trading lower by -0.19 percent ($-0.12) at $63.22 a piece in Tuesday’s session. It had closed the previous session at $63.34. MRK trades with a P/S ratio of 4.34. This is lower than the both industry’s 90.29 and the wider sector’s 13.11. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 15.2 and a trailing 12-month price-earnings (P/E) multiple of 34.43. Shares of MRK have uptrended 0.96% in the past three months, while the S&P 500 has moved -2.73% in that time. Merck & Co., Inc. (MRK) has a market cap of $173.62 billion and over the last 12 months, Merck & Co., Inc. (NYSE:MRK) has gone stronger by 2.76%. During the last 52 weeks, the (NYSE:MRK) price has been as high as $66.8 and as low as $58.29. Merck & Co., Inc. earnings have declined with an annualized rate of -7% over the last 5 years.

Merck & Co., Inc. (Mean Target Price: $68.43)

The average 1-year price target for Merck & Co., Inc. (MRK) — averaging the work of different analysts — reveals a mean PT of $68.43/share. That’s a potential 8.24 increase relative to where Merck & Co., Inc. (NYSE:MRK) has been trading recently. The current price is seen ranging between $62.88 and $63.31. There are brokerage firms with lower targets than the average, including one setting a price target of $55. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $73.

Merck & Co., Inc. (MRK) Consensus Recommendation

The collective rating of 2.3 for Merck & Co., Inc. (NYSE:MRK) also leans strongly towards the neutral end of the spectrum. Of the 21 analysts surveyed by Reuters that track MRK 7 of them rate its stock a hold. The other 14, though not evenly; between analysts who think you should buy Merck & Co., Inc. versus those who think you should sell it. A 13 analysts rate it as either a buy or a strong buy, while1 believe that investors should either steer clear of MRK or, if they already own its stock, sell it.

Is International Business Machines Corporation (NYSE:IBM) Cheap From Peers?

International Business Machines Corporation (IBM) knifed -0.2 percent lower and now trades for $146.54. IBM comes in with a P/S ratio of 1.74 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (13.11) and its peers (90.29). Also, it has an estimated price-earnings (P/E) multiple of 10.6 and a trailing 12-month price-earnings (P/E) multiple of 12.17. During the last 52 weeks, the price has been as high as $182.79 and as low as $139.13. International Business Machines Corporation (NYSE:IBM) earnings have declined with a quarterly rate of -5.7% over the last 5 years. Shares of IBM have sank -0.67% in the past three monthswhile the S&P 500 has dropped -7.73% in that time.

International Business Machines Corporation (Price Objective: $160.23)

International Business Machines Corporation (NYSE:IBM) has a market cap of $136.5 billion and over the last 12 months, IBM has declined by -5.32%. The average 1-year price target for (IBM) reveals an average price target of $160.23 per share. That’s a potential 9.34 gain from where (NYSE:IBM) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $125. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $200.

Analyst Thoughts About International Business Machines Corporation (NYSE:IBM)

The consensus recommendation — averaging the work of 26 analysts — of 2.8 for International Business Machines Corporation (IBM) points to moderate case. Of the analysts surveyed by Reuters that track International Business Machines Corporation 16 of them rate its stock a hold. The other 10 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 6 analysts rate it as either a buy or a strong buy, while 4 believe that investors should either steer clear of (NYSE:IBM) or, if they already own its stock, sell it.